Study Condition(s): Genital Psoriasis, Psoriasis

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q)

Study Alias: RHBQ

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02718898 {{ currentLocaleObject.registryAnchorText }}

Completed Completed

Study Purpose

The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.

Completed Study

The results of this study are not yet available.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18+ years

Time Commitment

Your participation could last up to 16 months and include 15 visits to the study center
  • Particpant must have a diagnosis of chronic plaque psoriasis for at least 6 months before entering the study

  • Participant must have moderate-to-severe psoriasis in the genital area at the time of entering the study

  • Participant must also have plaque psoriasis in a non-genital area at the time of entering the study

  • Participant must have failed to respond to, or are intolerant of, at least 1 topical therapy used for treatment of psoriasis affecting the genital area

  • Participant must agree to use reliable method of birth control, which could include abstinence, during the study and for at least 12 weeks following the last dose of study drug

  • Participant must not have Pustular, erythrodermic, and/or guttate forms of psoriasis or a history of drug-induced psoriasis

  • Participant must not have ever received treatment with ixekizumab, secukinumab, brodalumab, or another drug with a similar mode of action

  • Participant must avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to baseline and during the study

  • Participant must not currently have cancer or have had cancer within 5 years prior to baseline

  • Female participants must not be pregnant or breastfeeding

Where This Study Took Place Tool Tip Icon

33 locations participated
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.